Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis — Subgroup Analyses of the CALIPSO Trial
Sign Up to like & getrecommendations! Published in 2020 at "Kidney International Reports"
DOI: 10.1016/j.ekir.2020.09.032
Abstract: Introduction Coronary artery calcium (CAC) is highly prevalent and linked with poor outcomes in patients receiving maintenance hemodialysis, and its reduction may improve patient prognosis. SNF472, a selective inhibitor of hydroxyapatite crystallization, slows CAC progression… read more here.
Keywords: hemodialysis; inhibitor hydroxyapatite; trial; patients receiving ... See more keywords